EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CRISPR/Cas9-directed epigenetic editing in colorectal cancer

Manoj Kumar Gupta, Gayatri Gouda, Maryam Moazzam-Jazi, Ramakrishna Vadde, Ganji Purnachandra Nagaraju, Bassel F El-Rayes

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025

DOI: 10.1016/j.bbcan.2025.189338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Manoj Kumar Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover 30625, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, CRISPR-Cas Systems, Gene Editing, Epigenesis, Genetic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 259 Literaturangaben. Gefördert von: Medizinischen Hochschule Hannover, University of Alabama.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains a leading cause of cancer-related illness and death worldwide, arising from a complex interplay of genetic predisposition, environmental influences, and epigenetic dysregulation. Among these factors, epigenetic modifications-reversible and heritable changes in gene expression-serve as crucial regulators of CRC progression. Understanding these modifications is essential for identifying potential biomarkers for early diagnosis and developing targeted therapeutic strategies. Epigenetic drugs (epidrugs) such as DNA methyltransferase inhibitors (e.g., decitabine) and bromodomain inhibitors (e.g., JQ1) have shown promise in modulating aberrant epigenetic changes in CRC. However, challenges such as drug specificity, delivery, and safety concerns limit their clinical application. Advances in CRISPR-Cas9-based epigenetic editing offer a more precise approach to modifying specific epigenetic markers, presenting a potential breakthrough in CRC treatment. Despite its promise, CRISPR-based epigenome editing may result in unintended genetic modifications, necessitating stringent regulations and safety assessments. Beyond pharmacological interventions, lifestyle factors-including diet and gut microbiome composition-play a significant role in shaping the epigenetic landscape of CRC. Nutritional and microbiome-based interventions have shown potential in preventing CRC development by maintaining intestinal homeostasis and reducing tumor-promoting epigenetic changes. This review provides a comprehensive overview of epigenetic alterations in CRC, exploring their implications for diagnosis, prevention, and treatment. By integrating multi-omics approaches, single-cell technologies, and model organism studies, future research can enhance the specificity and efficacy of epigenetic-based therapies. Shortly, a combination of advanced gene-editing technologies, targeted epidrugs, and lifestyle interventions may pave the way for more effective and personalized CRC treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCRISPR-Cas SystemsGene EditingEpigenesis, GeneticHumansAnimalsDNA MethylationGene Expression Regulation, NeoplasticEpigenome Editing

Stichwörter der Autor:innen

CRISPR/Cas9Colorectal cancerDNA methylationEpigeneticsHistone modification

Autor:innen und Institutionen

  • Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover 30625, Germany.
  • ICAR-National Rice Research Institute, Cuttack 753 006, Odisha, India.
  • Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Biotechnology and Bioinformatics, Yogi Vemana University, Kadapa 516005, Andhra Pradesh, India.
  • Division of Hematology & Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35233, USA. Electronic address: pganji@uab.edu.
  • Division of Hematology & Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35233, USA. Electronic address: belrayes@uabmc.edu.

Förderung

  • Medizinischen Hochschule Hannover
  • University of Alabama

Zitieren

APA

Gupta, M. K., Gouda, G., Moazzam-Jazi, M., Vadde, R., Nagaraju, G. P., & El-Rayes, B. F. (2025). CRISPR/Cas9-directed epigenetic editing in colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189338

Vancouver

Gupta MK, Gouda G, Moazzam-Jazi M, Vadde R, Nagaraju GP, El-Rayes BF. CRISPR/Cas9-directed epigenetic editing in colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189338

BibTeX
@article{Gupta2025,
  author = {Gupta, Manoj Kumar and Gouda, Gayatri and Moazzam-Jazi, Maryam and Vadde, Ramakrishna and Nagaraju, Ganji Purnachandra and El-Rayes, Bassel F},
  title = {CRISPR/Cas9-directed epigenetic editing in colorectal cancer},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2025},
  doi = {10.1016/j.bbcan.2025.189338}
}
Kostenlos starten →